Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity
Executive Summary
On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.
You may also be interested in...
La Jolla’s Giapreza: Emergency Use Requests Sped US FDA Approval For Septic Shock
After publication of ATHOS-3 study results, agency received several requests from medical community for emergency use in hospitalized patients with shock and hypotension unresponsive to available therapy, spurring FDA to take an approval action two months ahead of user fee goal date.
Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections
Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.
89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.